MOTS-c before and after comparisons are photo pairs, scale weights and the occasional blood panel, and not one of them comes from a published human trial. No study has reported what this peptide does to human body composition over eight weeks, over twelve weeks, or over a year.
The vendor we point lifters to
MOTS-c from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
Buying 3, 5 or 10 vials takes 3%, 5% or 10% off the list price. Free shipping starts at $250, which one discounted vial does not reach.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 19, 2026.
That absence matters more here than it would for a compound with no story at all, because MOTS-c has a real mechanistic story attached to it. It is a peptide encoded inside mitochondrial DNA rather than in the nucleus, and the laboratory work on it points at fuel handling: glucose disposal, insulin sensitivity, the machinery that decides whether energy gets burned or stored. For an audience that tracks body fat and lean mass, that is a legitimately interesting place for a molecule to act. It is also exactly the sort of story that compresses into a claim about physique, and the compression is where the honesty goes.
Two different things get called a result
A before and after does two jobs at once, and they pull apart under any pressure.
The first job is documentation: something measurable differed between two dates. A lower scale weight, a smaller waist, a fasting glucose reading that moved. That part can be entirely true and still say nothing about cause.
The second job is attribution: the compound did it. Attribution requires a comparison the photograph does not contain. What would this person have looked like on the same training, the same food and the same sleep, without the vial? Nobody posting a personal transformation has that number, because producing it requires a control group, and a control group is what a trial is for.
Lifters already understand this in another context. Everyone has seen a training log where a programme change coincided with a diet change, a new job and a holiday, and the whole result gets credited to the programme. The reasoning error is identical, and it does not become sounder when a peptide is involved.
What MOTS-c before and after evidence actually exists
The honest inventory is short.
In mice, administration of MOTS-c has been reported to reduce diet induced weight gain and to improve measures of glucose handling and insulin sensitivity. Those findings are what the entire retail story rests on. In cultured cells, work has described effects on the folate and one carbon metabolic cycle with downstream activation of AMPK, an energy sensing pathway that pushes cells toward burning substrate rather than storing it.
In aged mice, treatment has been reported to improve physical performance measures including running capacity. That is the closest thing in the literature to a performance outcome, and it is a rodent result in old animals, not a training result in a person.
In humans, the relevant published work is observational rather than interventional. Circulating and skeletal muscle MOTS-c has been reported to rise after acute exercise in people, which says the peptide takes part in the body's own response to training. It does not say that adding more of it from outside reproduces or amplifies that response.
No interventional human study exists. One registry record names the peptide and reads as a recruiting Phase 2 trial, and a later section explains why it is not one. When someone shows you a transformation, the controlled comparison their photograph is standing in for has never been run by anybody.
Why a metabolic result is not a physique result
Suppose the mouse result held up in people and the peptide improved insulin sensitivity in adults with a metabolic deficit. What follows for a forty five year old lifter?
Less than the forums assume. Better insulin sensitivity is a reasonable thing to want, and in human physiology generally it is associated with easier nutrient partitioning. It is not a mechanism for adding contractile tissue. Nothing in this literature describes an action on the myostatin pathway, on satellite cells, or on muscle protein synthesis. No group is studying MOTS-c as an anabolic agent, in any species.
There is a second gap, and it is the one people skip. The animals in those experiments were made metabolically unwell on purpose, on a high fat diet, before anything was administered to them. Effects seen when a manufactured deficit gets corrected routinely shrink or vanish in trained, lean, already insulin sensitive people, because there is less to correct. A lifter who trains hard and eats deliberately is close to the ceiling on the variable being measured.
What a photograph can and cannot show
| What the image or log contains | What it can establish | What it cannot establish | Organism |
|---|---|---|---|
| Two photographs, weeks apart | That appearance changed | That the compound caused it | Human, uncontrolled |
| Scale weight over eight weeks | A net change in mass | Which tissue changed | Human, uncontrolled |
| A DEXA or bioimpedance pair | An estimated shift in composition | Change beyond measurement error | Human, uncontrolled |
| A fasting glucose or HbA1c pair | That a marker moved | That the peptide moved it | Human, uncontrolled |
| Rodent glucose tolerance testing | An effect under controlled conditions | Translation to a trained human | Mouse |
| A registry entry that reads as a trial | That a record was submitted | Anything whatever about the compound | None |
The last row is the one worth sitting with. The design capable of settling this has never been run, and the entry that appears to be it is not a study.
The confounds that eat most self reported results
Anyone buying a research peptide has already decided to change something, and that decision rarely arrives alone.
Water and glycogen shift several pounds in either direction inside a week in humans, with no change in fat or muscle at all. Photographs taken at different times of day, in different hydration states and under different lighting exaggerate the effect further. Training effort rises when someone believes an intervention is working, and effort is a genuine driver of body composition that ends up credited to the vial. Food intake tightens quietly over the same period. Sleep often improves, because the person has become interested in their own physiology again.
Then there is the supply problem, which is less a confound than an unknown. MOTS-c holds no marketing authorisation anywhere and is sold as a research chemical, so the contents of a vial are attested by the seller and verified by nobody. A before and after produced by an unidentified quantity of an unverified substance is not an experiment. It is an anecdote with a photograph attached.
The timeline nobody applies
Even granting the peptide an effect, the timing of most posted transformations does not fit one.
Meaningful change in fat free mass in a trained human is slow. Adding a pound of muscle takes weeks of accumulated stimulus in someone who is no longer a novice, and losing enough fat to show in a photograph takes a sustained deficit over a similar span. Reports of visible change within the first two or three weeks of anything are describing water, glycogen, posture, lighting and attention, because there has not been time for tissue to move.
Metabolic markers behave differently, which is why they get quoted. Fasting glucose in humans moves day to day with sleep, illness, recent training and the previous evening's meal, so a single pair of readings weeks apart carries a great deal of noise. HbA1c integrates over months and is steadier, which also means it responds too slowly to be the thing that changed in a four week report.
A claimed result is therefore worth checking against its own clock. Fast subjective change and slow objective change point in different directions, and the usual honest reading of a rapid transformation is that the fastest moving variable in the picture was the person's own behaviour.
The comparison the photographs stand in for does not exist
Everything above turns on a single absence: nobody has run the controlled study that a transformation post implicitly claims to substitute for. The usual reassurance is that the study is under way and will report. It is not, and the reason deserves a few paragraphs.
The record people point at is NCT07505745. On the registry it reads as a Phase 2 study, with an enrolment figure, a population of adults with prediabetes and overweight or obesity, insulin sensitivity as the stated question, and a status of recruiting. Checking that the identifier resolves returns all of that cleanly.
The lead sponsor settles it. The same sponsor name sits on seven further records submitted to the registry between February and April 2026, all listed as recruiting, all naming one hospital site, and covering between them peptides sold in the same catalogue as this one, down to two weight loss drugs. That is the shape of a product range, not of a research programme. One of the seven states in its own brief summary that it is a fictional example of a registry style record. The sponsor has no drug application on file with the FDA and no published work under its name.
For this page the consequence is unusually clean. A before and after is uncontrolled evidence, and the standard defence of quoting one anyway is that the controlled version is coming. It is not coming. There is no trial, no timetable and no pending readout, so the photographs are not a preview of a result that will arrive later. They are the entire human record on this compound, which is another way of saying there is no human record.
The habit worth taking from it applies to every peptide with a number attached to it. A registry accepts submissions and verifies none of them, so an identifier is a receipt rather than a result. Open the record, read the lead sponsor, search that sponsor for anything else it has ever done, and read the brief summary to the end. Three fields and one minute, and it is the difference between citing a study and citing a form.
Straight answers to the usual questions
Are there any published human before and after results for MOTS-c?
No, and none is pending. No genuine human interventional trial of this peptide is registered anywhere, so every transformation in circulation is uncontrolled personal reporting.
Does the exercise research mean supplementing it improves training?
Not established. Human work reporting a rise in MOTS-c after exercise describes the body's own response to a training stimulus. Whether administering the peptide reproduces that effect in people has not been tested.
Would a change in body fat over twelve weeks prove anything?
On its own, no. Twelve weeks of deliberate training and eating changes body composition in humans regardless of what else is taken, which is the entire reason controlled comparison exists.
Is there muscle building evidence in any species?
None. The animal and cell literature is metabolic. Nothing in it describes hypertrophy, myostatin inhibition or raised muscle protein synthesis in any organism.
What would a convincing result actually look like?
A controlled human trial with body composition as a stated endpoint, measured by a method with known error, in a training population, with results published. That study does not currently exist.
Reading someone else's transformation
The useful question is not whether the person posting is lying. Most are not. The useful question is what their photograph is evidence of, and the answer is that it is evidence of their own outcome under conditions nobody recorded.
For ageing muscle specifically, the levers with human data behind them stay unglamorous: resistance training the joints tolerate across years, protein high enough to matter, sleep, and enough continuity that training blocks are not repeatedly broken. MOTS-c is a genuinely interesting molecule with a plausible metabolic story and no human trial behind it. Interesting and unproven at the same time is an uncomfortable place to leave a compound, and it is exactly where the evidence sits.